Baidu
map
CANCER CYTOPATHOL 润色咨询

CANCER CYTOPATHOLOGY

出版年份：暂无数据 年文章数：938 投稿命中率： 开通期刊会员，数据随心看

出版周期：Bimonthly 自引率：18.6% 审稿周期： 开通期刊会员，数据随心看

前往期刊查询
期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=1238588, encodeId=faff1238588c3, content=请问有最近接收的吗？好中吗？求分享下经验，感恩的心！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faac6572097, createdName=ms9000000308331774, createdTime=Sun Aug 14 11:57:46 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560619, encodeId=749356061964, content=投稿真是秒拒啊。 I regret to inform you that the manuscript was not deemed to be within the top 20% of submitted manuscripts, and has not been accepted for publication in Cancer Cytopathology., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9122341099, createdName=1228f419m58(暂无昵称), createdTime=Sat Sep 01 09:43:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849396, encodeId=927d8493962a, content=总体而言是个很好的期刊，就是希望审稿再快点，能变成月刊就好了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f225414024, createdName=ms6336778790072332, createdTime=Mon Jan 21 17:00:51 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088380, encodeId=bd9c108838048, content=期刊发送的信件里需要注意几个方面的内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088379, encodeId=3f4f10883e9d5, content=如何写延期信？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803694, encodeId=d79c8036943c, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;代谢<br>经验分享：投的review，3个小时后就发了拒信，因为看了投稿内容觉得不是很符合他们的受众，推荐转投了另外一家同出版社的3.49的OA期刊，我同意了，现在不知道后续什么情况，如果接收了就来更。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Tue Jul 21 15:45:09 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590276, encodeId=bc625902e62b, content=这个杂志自引这么高，惠被踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df012074650, createdName=jxsrmscg, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561997, encodeId=579d56199e59, content=想问一下 ，没有人投这个杂志吗？能否给个评价看看呀，我打算投这个感觉国内的投的是不是少啊 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Mon Oct 15 10:58:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516602, encodeId=2e9b516602bb, content=版面费多少钱啊？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d6541241, createdName=drliuxiaoyun, createdTime=Thu Nov 05 22:56:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=511590, encodeId=003951159067, content=好像不是，应该是子刊<span class="quote">匿名 2014-07-03 发表::<br> 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？</span>, beContent=匿名 2014-07-03 发表:: 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.45.155, createdTime=Fri May 01 13:05:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2022-08-14 ms9000000308331774

    请问有最近接收的吗？好中吗？求分享下经验，感恩的心！

    1

    展开1条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=1238588, encodeId=faff1238588c3, content=请问有最近接收的吗？好中吗？求分享下经验，感恩的心！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faac6572097, createdName=ms9000000308331774, createdTime=Sun Aug 14 11:57:46 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560619, encodeId=749356061964, content=投稿真是秒拒啊。 I regret to inform you that the manuscript was not deemed to be within the top 20% of submitted manuscripts, and has not been accepted for publication in Cancer Cytopathology., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9122341099, createdName=1228f419m58(暂无昵称), createdTime=Sat Sep 01 09:43:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849396, encodeId=927d8493962a, content=总体而言是个很好的期刊，就是希望审稿再快点，能变成月刊就好了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f225414024, createdName=ms6336778790072332, createdTime=Mon Jan 21 17:00:51 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088380, encodeId=bd9c108838048, content=期刊发送的信件里需要注意几个方面的内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088379, encodeId=3f4f10883e9d5, content=如何写延期信？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803694, encodeId=d79c8036943c, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;代谢<br>经验分享：投的review，3个小时后就发了拒信，因为看了投稿内容觉得不是很符合他们的受众，推荐转投了另外一家同出版社的3.49的OA期刊，我同意了，现在不知道后续什么情况，如果接收了就来更。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Tue Jul 21 15:45:09 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590276, encodeId=bc625902e62b, content=这个杂志自引这么高，惠被踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df012074650, createdName=jxsrmscg, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561997, encodeId=579d56199e59, content=想问一下 ，没有人投这个杂志吗？能否给个评价看看呀，我打算投这个感觉国内的投的是不是少啊 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Mon Oct 15 10:58:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516602, encodeId=2e9b516602bb, content=版面费多少钱啊？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d6541241, createdName=drliuxiaoyun, createdTime=Thu Nov 05 22:56:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=511590, encodeId=003951159067, content=好像不是，应该是子刊<span class="quote">匿名 2014-07-03 发表::<br> 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？</span>, beContent=匿名 2014-07-03 发表:: 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.45.155, createdTime=Fri May 01 13:05:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2018-09-01 1228f419m58(暂无昵称)

    投稿真是秒拒啊。 I regret to inform you that the manuscript was not deemed to be within the top 20% of submitted manuscripts, and has not been accepted for publication in Cancer Cytopathology.

    1

    展开1条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=1238588, encodeId=faff1238588c3, content=请问有最近接收的吗？好中吗？求分享下经验，感恩的心！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faac6572097, createdName=ms9000000308331774, createdTime=Sun Aug 14 11:57:46 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560619, encodeId=749356061964, content=投稿真是秒拒啊。 I regret to inform you that the manuscript was not deemed to be within the top 20% of submitted manuscripts, and has not been accepted for publication in Cancer Cytopathology., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9122341099, createdName=1228f419m58(暂无昵称), createdTime=Sat Sep 01 09:43:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849396, encodeId=927d8493962a, content=总体而言是个很好的期刊，就是希望审稿再快点，能变成月刊就好了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f225414024, createdName=ms6336778790072332, createdTime=Mon Jan 21 17:00:51 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088380, encodeId=bd9c108838048, content=期刊发送的信件里需要注意几个方面的内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088379, encodeId=3f4f10883e9d5, content=如何写延期信？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803694, encodeId=d79c8036943c, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;代谢<br>经验分享：投的review，3个小时后就发了拒信，因为看了投稿内容觉得不是很符合他们的受众，推荐转投了另外一家同出版社的3.49的OA期刊，我同意了，现在不知道后续什么情况，如果接收了就来更。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Tue Jul 21 15:45:09 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590276, encodeId=bc625902e62b, content=这个杂志自引这么高，惠被踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df012074650, createdName=jxsrmscg, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561997, encodeId=579d56199e59, content=想问一下 ，没有人投这个杂志吗？能否给个评价看看呀，我打算投这个感觉国内的投的是不是少啊 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Mon Oct 15 10:58:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516602, encodeId=2e9b516602bb, content=版面费多少钱啊？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d6541241, createdName=drliuxiaoyun, createdTime=Thu Nov 05 22:56:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=511590, encodeId=003951159067, content=好像不是，应该是子刊<span class="quote">匿名 2014-07-03 发表::<br> 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？</span>, beContent=匿名 2014-07-03 发表:: 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.45.155, createdTime=Fri May 01 13:05:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2019-01-21 ms6336778790072332

    总体而言是个很好的期刊，就是希望审稿再快点，能变成月刊就好了

    1

    展开1条回复
  4. [GetPortalCommentsPageByObjectIdResponse(id=1238588, encodeId=faff1238588c3, content=请问有最近接收的吗？好中吗？求分享下经验，感恩的心！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faac6572097, createdName=ms9000000308331774, createdTime=Sun Aug 14 11:57:46 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560619, encodeId=749356061964, content=投稿真是秒拒啊。 I regret to inform you that the manuscript was not deemed to be within the top 20% of submitted manuscripts, and has not been accepted for publication in Cancer Cytopathology., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9122341099, createdName=1228f419m58(暂无昵称), createdTime=Sat Sep 01 09:43:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849396, encodeId=927d8493962a, content=总体而言是个很好的期刊，就是希望审稿再快点，能变成月刊就好了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f225414024, createdName=ms6336778790072332, createdTime=Mon Jan 21 17:00:51 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088380, encodeId=bd9c108838048, content=期刊发送的信件里需要注意几个方面的内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088379, encodeId=3f4f10883e9d5, content=如何写延期信？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803694, encodeId=d79c8036943c, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;代谢<br>经验分享：投的review，3个小时后就发了拒信，因为看了投稿内容觉得不是很符合他们的受众，推荐转投了另外一家同出版社的3.49的OA期刊，我同意了，现在不知道后续什么情况，如果接收了就来更。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Tue Jul 21 15:45:09 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590276, encodeId=bc625902e62b, content=这个杂志自引这么高，惠被踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df012074650, createdName=jxsrmscg, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561997, encodeId=579d56199e59, content=想问一下 ，没有人投这个杂志吗？能否给个评价看看呀，我打算投这个感觉国内的投的是不是少啊 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Mon Oct 15 10:58:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516602, encodeId=2e9b516602bb, content=版面费多少钱啊？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d6541241, createdName=drliuxiaoyun, createdTime=Thu Nov 05 22:56:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=511590, encodeId=003951159067, content=好像不是，应该是子刊<span class="quote">匿名 2014-07-03 发表::<br> 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？</span>, beContent=匿名 2014-07-03 发表:: 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.45.155, createdTime=Fri May 01 13:05:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2021-12-28 ms6000000264964247

    期刊发送的信件里需要注意几个方面的内容？

    1

    展开1条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=1238588, encodeId=faff1238588c3, content=请问有最近接收的吗？好中吗？求分享下经验，感恩的心！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faac6572097, createdName=ms9000000308331774, createdTime=Sun Aug 14 11:57:46 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560619, encodeId=749356061964, content=投稿真是秒拒啊。 I regret to inform you that the manuscript was not deemed to be within the top 20% of submitted manuscripts, and has not been accepted for publication in Cancer Cytopathology., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9122341099, createdName=1228f419m58(暂无昵称), createdTime=Sat Sep 01 09:43:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849396, encodeId=927d8493962a, content=总体而言是个很好的期刊，就是希望审稿再快点，能变成月刊就好了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f225414024, createdName=ms6336778790072332, createdTime=Mon Jan 21 17:00:51 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088380, encodeId=bd9c108838048, content=期刊发送的信件里需要注意几个方面的内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088379, encodeId=3f4f10883e9d5, content=如何写延期信？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803694, encodeId=d79c8036943c, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;代谢<br>经验分享：投的review，3个小时后就发了拒信，因为看了投稿内容觉得不是很符合他们的受众，推荐转投了另外一家同出版社的3.49的OA期刊，我同意了，现在不知道后续什么情况，如果接收了就来更。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Tue Jul 21 15:45:09 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590276, encodeId=bc625902e62b, content=这个杂志自引这么高，惠被踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df012074650, createdName=jxsrmscg, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561997, encodeId=579d56199e59, content=想问一下 ，没有人投这个杂志吗？能否给个评价看看呀，我打算投这个感觉国内的投的是不是少啊 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Mon Oct 15 10:58:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516602, encodeId=2e9b516602bb, content=版面费多少钱啊？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d6541241, createdName=drliuxiaoyun, createdTime=Thu Nov 05 22:56:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=511590, encodeId=003951159067, content=好像不是，应该是子刊<span class="quote">匿名 2014-07-03 发表::<br> 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？</span>, beContent=匿名 2014-07-03 发表:: 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.45.155, createdTime=Fri May 01 13:05:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2021-12-28 小动量

    如何写延期信？

    1

    展开1条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=1238588, encodeId=faff1238588c3, content=请问有最近接收的吗？好中吗？求分享下经验，感恩的心！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faac6572097, createdName=ms9000000308331774, createdTime=Sun Aug 14 11:57:46 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560619, encodeId=749356061964, content=投稿真是秒拒啊。 I regret to inform you that the manuscript was not deemed to be within the top 20% of submitted manuscripts, and has not been accepted for publication in Cancer Cytopathology., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9122341099, createdName=1228f419m58(暂无昵称), createdTime=Sat Sep 01 09:43:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849396, encodeId=927d8493962a, content=总体而言是个很好的期刊，就是希望审稿再快点，能变成月刊就好了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f225414024, createdName=ms6336778790072332, createdTime=Mon Jan 21 17:00:51 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088380, encodeId=bd9c108838048, content=期刊发送的信件里需要注意几个方面的内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088379, encodeId=3f4f10883e9d5, content=如何写延期信？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803694, encodeId=d79c8036943c, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;代谢<br>经验分享：投的review，3个小时后就发了拒信，因为看了投稿内容觉得不是很符合他们的受众，推荐转投了另外一家同出版社的3.49的OA期刊，我同意了，现在不知道后续什么情况，如果接收了就来更。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Tue Jul 21 15:45:09 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590276, encodeId=bc625902e62b, content=这个杂志自引这么高，惠被踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df012074650, createdName=jxsrmscg, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561997, encodeId=579d56199e59, content=想问一下 ，没有人投这个杂志吗？能否给个评价看看呀，我打算投这个感觉国内的投的是不是少啊 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Mon Oct 15 10:58:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516602, encodeId=2e9b516602bb, content=版面费多少钱啊？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d6541241, createdName=drliuxiaoyun, createdTime=Thu Nov 05 22:56:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=511590, encodeId=003951159067, content=好像不是，应该是子刊<span class="quote">匿名 2014-07-03 发表::<br> 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？</span>, beContent=匿名 2014-07-03 发表:: 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.45.155, createdTime=Fri May 01 13:05:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2020-07-21 1486c94em67暂无昵称

    审稿速度:1.0 | 投稿命中率:50.0
    偏重的研究方向：肿瘤;代谢
    经验分享：投的review，3个小时后就发了拒信，因为看了投稿内容觉得不是很符合他们的受众，推荐转投了另外一家同出版社的3.49的OA期刊，我同意了，现在不知道后续什么情况，如果接收了就来更。

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1238588, encodeId=faff1238588c3, content=请问有最近接收的吗？好中吗？求分享下经验，感恩的心！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faac6572097, createdName=ms9000000308331774, createdTime=Sun Aug 14 11:57:46 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560619, encodeId=749356061964, content=投稿真是秒拒啊。 I regret to inform you that the manuscript was not deemed to be within the top 20% of submitted manuscripts, and has not been accepted for publication in Cancer Cytopathology., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9122341099, createdName=1228f419m58(暂无昵称), createdTime=Sat Sep 01 09:43:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849396, encodeId=927d8493962a, content=总体而言是个很好的期刊，就是希望审稿再快点，能变成月刊就好了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f225414024, createdName=ms6336778790072332, createdTime=Mon Jan 21 17:00:51 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088380, encodeId=bd9c108838048, content=期刊发送的信件里需要注意几个方面的内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088379, encodeId=3f4f10883e9d5, content=如何写延期信？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803694, encodeId=d79c8036943c, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;代谢<br>经验分享：投的review，3个小时后就发了拒信，因为看了投稿内容觉得不是很符合他们的受众，推荐转投了另外一家同出版社的3.49的OA期刊，我同意了，现在不知道后续什么情况，如果接收了就来更。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Tue Jul 21 15:45:09 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590276, encodeId=bc625902e62b, content=这个杂志自引这么高，惠被踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df012074650, createdName=jxsrmscg, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561997, encodeId=579d56199e59, content=想问一下 ，没有人投这个杂志吗？能否给个评价看看呀，我打算投这个感觉国内的投的是不是少啊 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Mon Oct 15 10:58:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516602, encodeId=2e9b516602bb, content=版面费多少钱啊？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d6541241, createdName=drliuxiaoyun, createdTime=Thu Nov 05 22:56:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=511590, encodeId=003951159067, content=好像不是，应该是子刊<span class="quote">匿名 2014-07-03 发表::<br> 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？</span>, beContent=匿名 2014-07-03 发表:: 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.45.155, createdTime=Fri May 01 13:05:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2020-05-05 jxsrmscg

    这个杂志自引这么高，惠被踢么

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1238588, encodeId=faff1238588c3, content=请问有最近接收的吗？好中吗？求分享下经验，感恩的心！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faac6572097, createdName=ms9000000308331774, createdTime=Sun Aug 14 11:57:46 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560619, encodeId=749356061964, content=投稿真是秒拒啊。 I regret to inform you that the manuscript was not deemed to be within the top 20% of submitted manuscripts, and has not been accepted for publication in Cancer Cytopathology., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9122341099, createdName=1228f419m58(暂无昵称), createdTime=Sat Sep 01 09:43:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849396, encodeId=927d8493962a, content=总体而言是个很好的期刊，就是希望审稿再快点，能变成月刊就好了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f225414024, createdName=ms6336778790072332, createdTime=Mon Jan 21 17:00:51 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088380, encodeId=bd9c108838048, content=期刊发送的信件里需要注意几个方面的内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088379, encodeId=3f4f10883e9d5, content=如何写延期信？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803694, encodeId=d79c8036943c, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;代谢<br>经验分享：投的review，3个小时后就发了拒信，因为看了投稿内容觉得不是很符合他们的受众，推荐转投了另外一家同出版社的3.49的OA期刊，我同意了，现在不知道后续什么情况，如果接收了就来更。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Tue Jul 21 15:45:09 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590276, encodeId=bc625902e62b, content=这个杂志自引这么高，惠被踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df012074650, createdName=jxsrmscg, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561997, encodeId=579d56199e59, content=想问一下 ，没有人投这个杂志吗？能否给个评价看看呀，我打算投这个感觉国内的投的是不是少啊 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Mon Oct 15 10:58:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516602, encodeId=2e9b516602bb, content=版面费多少钱啊？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d6541241, createdName=drliuxiaoyun, createdTime=Thu Nov 05 22:56:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=511590, encodeId=003951159067, content=好像不是，应该是子刊<span class="quote">匿名 2014-07-03 发表::<br> 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？</span>, beContent=匿名 2014-07-03 发表:: 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.45.155, createdTime=Fri May 01 13:05:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2018-10-15 1215fa24m64(暂无昵称)

    想问一下 ，没有人投这个杂志吗？能否给个评价看看呀，我打算投这个感觉国内的投的是不是少啊

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1238588, encodeId=faff1238588c3, content=请问有最近接收的吗？好中吗？求分享下经验，感恩的心！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faac6572097, createdName=ms9000000308331774, createdTime=Sun Aug 14 11:57:46 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560619, encodeId=749356061964, content=投稿真是秒拒啊。 I regret to inform you that the manuscript was not deemed to be within the top 20% of submitted manuscripts, and has not been accepted for publication in Cancer Cytopathology., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9122341099, createdName=1228f419m58(暂无昵称), createdTime=Sat Sep 01 09:43:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849396, encodeId=927d8493962a, content=总体而言是个很好的期刊，就是希望审稿再快点，能变成月刊就好了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f225414024, createdName=ms6336778790072332, createdTime=Mon Jan 21 17:00:51 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088380, encodeId=bd9c108838048, content=期刊发送的信件里需要注意几个方面的内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088379, encodeId=3f4f10883e9d5, content=如何写延期信？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803694, encodeId=d79c8036943c, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;代谢<br>经验分享：投的review，3个小时后就发了拒信，因为看了投稿内容觉得不是很符合他们的受众，推荐转投了另外一家同出版社的3.49的OA期刊，我同意了，现在不知道后续什么情况，如果接收了就来更。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Tue Jul 21 15:45:09 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590276, encodeId=bc625902e62b, content=这个杂志自引这么高，惠被踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df012074650, createdName=jxsrmscg, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561997, encodeId=579d56199e59, content=想问一下 ，没有人投这个杂志吗？能否给个评价看看呀，我打算投这个感觉国内的投的是不是少啊 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Mon Oct 15 10:58:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516602, encodeId=2e9b516602bb, content=版面费多少钱啊？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d6541241, createdName=drliuxiaoyun, createdTime=Thu Nov 05 22:56:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=511590, encodeId=003951159067, content=好像不是，应该是子刊<span class="quote">匿名 2014-07-03 发表::<br> 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？</span>, beContent=匿名 2014-07-03 发表:: 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.45.155, createdTime=Fri May 01 13:05:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2015-11-05 drliuxiaoyun

    版面费多少钱啊？？

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1238588, encodeId=faff1238588c3, content=请问有最近接收的吗？好中吗？求分享下经验，感恩的心！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=89, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=faac6572097, createdName=ms9000000308331774, createdTime=Sun Aug 14 11:57:46 CST 2022, time=2022-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=560619, encodeId=749356061964, content=投稿真是秒拒啊。 I regret to inform you that the manuscript was not deemed to be within the top 20% of submitted manuscripts, and has not been accepted for publication in Cancer Cytopathology., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9122341099, createdName=1228f419m58(暂无昵称), createdTime=Sat Sep 01 09:43:00 CST 2018, time=2018-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=849396, encodeId=927d8493962a, content=总体而言是个很好的期刊，就是希望审稿再快点，能变成月刊就好了 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=201, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f225414024, createdName=ms6336778790072332, createdTime=Mon Jan 21 17:00:51 CST 2019, time=2019-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088380, encodeId=bd9c108838048, content=期刊发送的信件里需要注意几个方面的内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1088379, encodeId=3f4f10883e9d5, content=如何写延期信？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=82, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/e664bd00445a497ca6dfc89ec35b9206/0bfbc1258d9f4ec6aba6990cbd76f3e2.jpg, createdBy=e9d85497901, createdName=小动量, createdTime=Tue Dec 28 14:52:48 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=803694, encodeId=d79c8036943c, content=审稿速度:1.0 | 投稿命中率:50.0<br>偏重的研究方向：肿瘤;代谢<br>经验分享：投的review，3个小时后就发了拒信，因为看了投稿内容觉得不是很符合他们的受众，推荐转投了另外一家同出版社的3.49的OA期刊，我同意了，现在不知道后续什么情况，如果接收了就来更。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30e45293950, createdName=1486c94em67暂无昵称, createdTime=Tue Jul 21 15:45:09 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590276, encodeId=bc625902e62b, content=这个杂志自引这么高，惠被踢么, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=212, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df012074650, createdName=jxsrmscg, createdTime=Tue May 05 00:00:00 CST 2020, time=2020-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561997, encodeId=579d56199e59, content=想问一下 ，没有人投这个杂志吗？能否给个评价看看呀，我打算投这个感觉国内的投的是不是少啊 <br> , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=382, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7f382249352, createdName=1215fa24m64(暂无昵称), createdTime=Mon Oct 15 10:58:00 CST 2018, time=2018-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=516602, encodeId=2e9b516602bb, content=版面费多少钱啊？？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=558, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6d6541241, createdName=drliuxiaoyun, createdTime=Thu Nov 05 22:56:00 CST 2015, time=2015-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=511590, encodeId=003951159067, content=好像不是，应该是子刊<span class="quote">匿名 2014-07-03 发表::<br> 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？</span>, beContent=匿名 2014-07-03 发表:: 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=312, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=117.136.45.155, createdTime=Fri May 01 13:05:00 CST 2015, time=2015-05-01, status=1, ipAttribution=)]
    2015-05-01 117.136.45.155

    好像不是，应该是子刊匿名 2014-07-03 发表::
    请问Cancer 和 Cancer Cytopathology是同一个杂志吗？

    匿名 2014-07-03 发表:: 请问Cancer 和 Cancer Cytopathology是同一个杂志吗？

    0

共24条页码: 1/3页10条/页
分享您的投稿经验，提升MI经验值，获取更多积分

Baidu
Baidu
map
Baidu
map
Baidu
map